Home＞REGULATORY
Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015(Sep.26.2017)
By Reiji Anasako
The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was revealed that doctors were indeed shying away from prescribing these medicines in the elderly age 75 and older amid swirling side effect concerns over the class ...
(LOG IN FOR FULL STORY)
The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was revealed that doctors were indeed shying away from prescribing these medicines in the elderly age 75 and older amid swirling side effect concerns over the class ...
-
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients Oct.17
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW Oct.17
- As Abe Vows to Deliver on Tax Hike Plan, 3 Pharma Groups to Push for October 2019 Price Revision Oct.16
- MEXT Kicks Off “Open Innovation Organization” Initiative, 3 Universities to Push Drug Discovery Oct.15
-
Nobel Laurate Honjo Prods Minister on Industry Consolidation
Oct.12
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near(Oct.17)
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients(Oct.17)
- Eisai Seals Latin America Pact for Belviq(Oct.17)
- Teva Takeda Launches Voluntary Recall for Taxotere Generics(Oct.17)
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW(Oct.17)
